PTSD (post-traumatic stress disorder)
The current clinical standard of the Diagnostic and Statistical Manual of mental disorders (DSM-5), post-traumatic stress disorder (PTSD) may develop after an individual has been through an experience that is life-threatening or posed the potential of serious bodily harm to self, or others. The main impact of these symptoms comes from the fact that they persist into an individual's life, overwhelming their ability to maintain healthy physiological and emotional equilibrium. When an individual is unable to overcome the acute stress response symptoms of fear, dread, anxiety, intrusive memories and/or dreams of the trauma, the chronic condition that characterizes post-traumatic stress ensues. PTSD symptoms are often precipitated by financial stress, marital discord, natural disasters, automobile accidents, personal or terrorist attacks, sexual violence, or combat exposure, among others.
The neurological and physiological nature of PTSD symptoms can have dire consequences on one's physical and mental health. The disruption of the endocrine and nervous systems, such as the chronic activation of the sympathetic fight-or-flight response, have been clinically associated with many other health conditions.
Current statistics and epidimeology of PTSD
over two thousand children found that just over 30% reported trauma, and nearly 8% experienced PTSD by 18years of age
Around 6 out of 100 people (6% of the US population) will have PTSD at some point in their lives
About 5 out of 100 people will have PTSD in any given year
Military personnel, and first responders are at higher risk for developing PTSD than the general population
Over 40% of those with PTSD develop major depressive disorder
Research on PTSD over the past 20+ years shows:
Often characterized by symptoms of sleep disorder, substance abuse, and mood dysregulation
Pharmaceutical medicine predisposes individuals to dependence and increased tolerance
PTSD is associated with physiological markers that are associated with poor immune and cardiovascular function
Reduction in alpha brainwave activity is a clinically valid marker of the hyperarousal that is universally found in PTSD cases
A systematic review of 21 studies showed a very small effect size between medication and placebo interventions
Brain wave (EEG) analyses have shown that dysregulated function of the posterior cingulate cortex (PCC) portion of the brain is a common feature of PTSD
Neurofeedback targets specific trauma brain parameters
Uses personalized QEEG analysis to confirm which sites of the brain show dysregulation
“alpha-theta” has shown clinical superiority that ranged up to 80% success rate in alleviating symptoms and long-term effects of PTSD in combat veterans.
Neurofeedback has shown to be so successful in recalibrating the function of the PCC that even a single session showed a reduction in hyperarousal scores
The brain’s anatomical and functional malleability (neuroplasticity) allows neurofeedback to reinforce brain activity that is associated with a healthy EEG range
The “alpha-theta” protocol commonly used in substance abuse treatment has shown no less than a 70% success rate in treatment
Research conducted under Bessel Van Der Kolk, Ph.D. has shown that neurofeedback has shown that over 70% of subject no longer met criteria for PTSD after 24 sessions
Although traumatic events can take many forms, modern technology is now able to identify and address the effects that it has upon the brain, which offers tremendous hope to public health and human progress as a whole. The impediments to true human potential are able to be surmounted and abated by the promise that neurofeedback holds. Click here for more information
Treating PTSD & Substance Abuse wih Neurofeedback (WATCH NOW)
References:
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182008/
2. https://www.ncbi.nlm.nih.gov/books/NBK207191/box/part1_ch3.box16/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555259/
4. http://michiganbraincoretherapy.com/storage/PTSD/PENISTONPTSD.pdf
5. https://www.proquest.com/docview/193497792
6. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166752
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013955/
8. http://braintrainut.com/wp-content/uploads/2013/10/Peniston-alpha-theta-PTSD.pdf